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Summary
Background Treatment of dysplastic Barrett’s oesophagus prevents progression to adenocarcinoma; however, the 
optimal diagnostic strategy for Barrett’s oesophagus is unclear. The Cytosponge-trefoil factor 3 (TFF3) is a non-
endoscopic test for Barrett’s oesophagus. The aim of this study was to investigate whether offering this test to patients 
on medication for gastro-oesophageal reflux would increase the detection of Barrett’s oesophagus compared with 
standard management.
Methods This multicentre, pragmatic, randomised controlled trial was done in 109 socio-demographically diverse 
general practice clinics in England. Randomisation was done both at the general practice clinic level (cluster 
randomisation) and at the individual patient level, and the results for each type of randomisation were analysed 
separately before being combined. Patients were eligible if they were aged 50 years or older, had been taking acid-
suppressants for symptoms of gastro-oesophageal reflux for more than 6 months, and had not undergone an 
endoscopy procedure within the past 5 years. General practice clinics were selected by the local clinical research 
network and invited to participate in the trial. For cluster randomisation, clinics were randomly assigned (1:1) by the 
trial statistician using a computer-generated randomisation sequence; for individual patient-level randomisation, 
patients were randomly assigned (1:1) by the general practice clinics using a centrally prepared computer-generated 
randomisation sequence. After randomisation, participants received either standard management of gastro-
oesophageal reflux (usual care group), in which participants only received an endoscopy if required by their general 
practitioner, or usual care plus an offer of the Cytosponge-TFF3 procedure, with a subsequent endoscopy if the 
procedure identified TFF3-positive cells (intervention group). The primary outcome was the diagnosis of Barrett’s 
oesophagus at 12 months after enrolment, expressed as a rate per 1000 person-years, in all participants in the 
intervention group (regardless of whether they had accepted the offer of the Cytosponge-TFF3 procedure) compared 
with all participants in the usual care group. Analyses were intention-to-treat. The trial is registered with the ISRCTN 
registry, ISRCTN68382401, and is completed.
Findings Between March 20, 2017, and March 21, 2019, 113 general practice clinics were enrolled, but four clinics 
dropped out shortly after randomisation. Using an automated search of the electronic prescribing records of the 
remaining 109 clinics, we identified 13 657 eligible patients who were sent an introductory letter with 14 days to opt 
out. 13 514 of these patients were randomly assigned (per practice or at the individual patient level) to the usual care 
group (n=6531) or the intervention group (n=6983). Following randomisation, 149 (2%) of 6983 participants in the 
intervention group and 143 (2%) of 6531 participants in the usual care group, on further scrutiny, did not meet all 
eligibility criteria or withdrew from the study. Of the remaining 6834 participants in the intervention group, 
2679 (39%) expressed an interest in undergoing the Cytosponge-TFF3 procedure. Of these, 1750 (65%) met all of 
the eligibility criteria on telephone screening and underwent the procedure. Most of these participants (1654 [95%]; 
median age 69 years) swallowed the Cytosponge successfully and produced a sample. 231 (3%) of 6834 participants 
had a positive Cytosponge-TFF3 result and were referred for an endoscopy. Patients who declined the offer of the 
Cytosponge-TFF3 procedure and all participants in the usual care group only had an endoscopy if deemed necessary 
by their general practitioner. During an average of 12 months of follow-up, 140 (2%) of 6834 participants in the 
intervention group and 13 (<1%) of 6388 participants in the usual care group were diagnosed with Barrett’s 
oesophagus (absolute difference 18·3 per 1000 person-years [95% CI 14·8–21·8]; rate ratio adjusted for cluster 
randomisation 10·6 [95% CI 6·0–18·8], p<0·0001). Nine (<1%) of 6834 participants were diagnosed with dysplastic 
Barrett’s oesophagus (n=4) or stage I oesophago-gastric cancer (n=5) in the intervention group, whereas no 
participants were diagnosed with dysplastic Barrett’s oesophagus or stage I gastro-oesophageal junction cancer in 
the usual care group. Among 1654 participants in the intervention group who swallowed the Cytosponge device 
successfully, 221 (13%) underwent endoscopy after testing positive for TFF3 and 131 (8%, corresponding to 59% of 
those having an endoscopy) were diagnosed with Barrett’s oesophagus or cancer. One patient had a detachment of 
the Cytosponge from the thread requiring endoscopic removal, and the most common side-effect was a sore throat 
in 63 (4%) of 1654 participants.
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Introduction
Heartburn symptoms caused by gastro-oesophageal 
reflux disease are common, affecting up to 20% of adults 
in northwest Europe, North America, Australia, and 
New Zealand and leading to enormous annual health-
care costs.1,2 Most of these individuals do not have a 
diagnosis and are treated over many years with acid-
suppres sant medication therapy. Symptoms of heartburn 
are impor tant when one considers the link between 
heartburn and oesophago-gastric cancer.3 It is estimated 
that 3–6% of individuals with gastro-oesophageal reflux-
predominant symptoms could have the precursor lesion 
to oesophageal adenocarcinoma, known as Barrett’s 
oesophagus. However, only around 20% of patients with 
Barrett’s oesophagus are diagnosed. Therefore, most 
cases of oesophageal adenocarcinoma are diagnosed de 
novo, without the opportunity to prevent progression.4–6
The incidence of oesophageal adenocarcinoma is six 
times higher than it was in the 1990s. Oesophageal 
adenocarcinoma also has a dismal prog nosis due to 
late presentation, with an overall 5-year survival of less 
than 20%, despite advances in neoadjuvant therapy 
and surgery.7,8 Clinical guidelines recommend urgent 
referral for an endoscopy in patients with warning symp-
toms, such as dysphagia and weight loss, and routine 
referral for an endoscopy in those with symptoms of 
gastro-oesophageal reflux that persist despite recom-
mended lifestyle and pharmacological management 
strategies, and those with multiple addi tional risk factors 
for the disease.9–12 Nevertheless, the proportion of 
patients referred for an endoscopy from general practice 
clinics varies widely, and the referral rates per practice 
correlate with the stage at diagnosis.13 A modelling 
study14 using data from the USA estimated that the 
burden of oesophageal adenocarcinoma could be 
reduced by up to 50% through implementing strategies 
for the systematic screening and early diagnosis of 
individuals with gastro-oesophageal reflux, who would 
otherwise not have been referred for an endoscopy.
Early detection needs to be combined with effective 
interventions to be clinically beneficial. There have been 
important advances in outpatient-based endoscopic 
therapies, which are now recommended for low-grade 
and high-grade dysplasia in Barrett’s oesoph agus, with 
low rates of recurrence.15–17 Patients with intramucosal 
stage I cancers have a survival of more than 90% and can 
be treated endoscopically, thus mitigating the risks of 
and side-effects from systemic therapy and an oesopha-
gectomy, which is often required for more advanced 
disease.18,19
In view of the scale of gastro-oesophageal reflux 
disease, and the costs (both psychological and financial) 
of investigation, any new clinical strategy needs to be 
carefully evaluated. We have developed a test for Barrett’s 
oesophagus that is suitable for use in the primary 
care setting. The test comprises a non-endoscopic cell 
collection device coupled with an in vitro test for the 
specific biomarker, trefoil factor 3 (TFF3), that identifies 
Interpretation In patients with gastro-oesophageal reflux, the offer of Cytosponge-TFF3 testing results in improved 
detection of Barrett’s oesophagus. Cytosponge-TFF3 testing could also lead to the diagnosis of treatable dysplasia and 
early cancer. This strategy will lead to additional endoscopies with some false positive results.
Funding Cancer Research UK, National Institute for Health Research, the UK National Health Service, Medtronic, 
and the Medical Research Council.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Research in context
Evidence before this study
Barrett’s oesophagus is a precancerous condition, which, 
if diagnosed, can permit early detection and curative treatment 
of dysplasia and oesophageal adenocarcinoma. The Cytosponge-
trefoil factor 3 (TFF3) test is a novel non-endoscopic cell 
collection device coupled with an immunohistochemical 
biomarker that can diagnose Barrett’s oesophagus in the 
primary care setting. Clinical studies to date have shown 
promising data on the safety, acceptability, accuracy, and cost-
effectiveness of this technique. 
Added value of this study
This is the first randomised controlled trial to show that offering 
the Cytosponge-TFF3 test to patients taking acid-suppressant 
therapy for symptoms of gastro-oesophageal reflux in primary 
care improves the detection of Barrett’s oesophagus and early 
cancer when compared with usual clinical practice.
Implications of all the available evidence
Improved detection of Barrett’s oesophagus, high patient 
acceptability, and few adverse events suggest that the 
Cytosponge-TFF3 technique could be adopted as a diagnostic 
triage test on a large scale.
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intestinal metaplasia (the histopathological hallmark of 
Barrett’s oesophagus;20 figure 1). Thus far, two clinical 
studies21,22 of this new clinical strategy, termed the 
Cytosponge-TFF3 procedure, have been done in over 
2000 patients, with promising data on safety, acceptability, 
accuracy, and cost-effectiveness.23–25
We did this pragmatic, randomised controlled trial, 
involving patients with recurrent symptoms of gastro-
oesophageal reflux who had been taking acid-suppressant 
medication prescribed by their general practitioner, to 
inves tigate whether the Cytosponge-TFF3 test, admin-
istered in the community setting, leads to the identification 
of more patients with Barrett’s oesophagus than does 
usual clinical practice for endoscopy referral in England.
Methods
Study design and participants
This multicentre, pragmatic, randomised controlled trial 
took place in 109 socio-demographically diverse general 
prac tice clinics in England (appendix pp 129–130).
Patients were eligible for inclusion if they were 
aged 50 years or older and had records of having been 
prescribed acid-suppressant therapy (proton-pump inhi-
bitor or histamine-2 receptor antagonists) for at least 
6 months in the previous year. Patients with records of 
having been prescribed non-steroidal anti-inflammatory 
drugs together with acid-suppressant therapy, suggesting 
that their reflux symptoms were not the primary basis for 
the proton-pump inhibitor prescription, and patients who 
had undergone an endoscopy in the previous 5 years or 
with a previous diagnosis of Barrett’s oesophagus, were 
excluded from the study.
All potential participants received an introductory letter 
to the study and were given 14 days to opt out, after which 
point they were enrolled in the trial.
The study protocol, which was approved by a central 
ethics committee, has been made publicly available 
(appendix pp 3–86).26 Aggregated data were collected 
from participating primary care clinics for all potential 
participants who did not opt out. Written informed 
consent was obtained before collecting any individual-
level patient data and before any clinical procedure was 
done.
Randomisation and masking
Initially, general practice clinics (ie, clusters) were 
randomly assigned (1:1) to either the usual care group, 
in which eligible patients with gastro-oesophageal reflux 
under the care of these clinics received standard 
management of their symptoms and were only referred for 
an endoscopy if required, or the intervention group, in 
which eligible patients received standard management 
and were offered the Cytosponge-TFF3 procedure, with 
a sub sequent endoscopy if the procedure identified TFF3-
positive cells. Approximately two-thirds of the way through 
recruitment, the trial switched to an individual patient-
level randomisation approach, which was approved by an 
independent trial steering committee, the research ethics 
committee, and the Medicines and Healthcare products 
Regulatory Agency (MHRA). Cluster randomisation was 
initially chosen in order to remove selection bias by general 
Figure 1: Comparison of the Cytosponge-TFF3 procedure with the endoscopy procedure 
(A) Administration and passage of the Cytosponge-TFF3 device to obtain a sample of oesophageal epithelial cells. 
(B) Administration and passage of an endoscope to visualise the oesophagus. The Cytosponge-TFF3 sample is 
processed to a paraffin block and stained with an antibody against (C) TFF3 and with (D) haematoxylin and 
eosin (magnification ×200). (E) Endoscopic white light view of Barrett’s oesophagus in deep red compared with 
surrounding light pink squamous epithelium. (F) One or more endoscopic biopsies are taken and the tissues are 
stained with haematoxylin and eosin for histopathological assessment (magnification ×200). (A) and (B) were 
drawn by Campbell Medical Illustration (Glasgow, Scotland). TFF3=trefoil factor 3.
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practitioners; however, in the trial, all patients were 
selected by use of the prescribing database, so selection 
bias was not an issue. After recommendation by the 
trial steering committee, we switched to individual 
randomisation during the study, which substantially 
increased the statistical power and also satisfied patient 
and clinician demand for the Cytosponge procedure to be 
available in all clinics. Data from both the cluster and 
individual randomisations were analysed separately before 
they were combined, having established that their results 
were consistent, as required by an independent data 
monitoring committee and the MHRA (appendix pp 87–89).
The trial statistician did the cluster randomisation of 
general practice clinics by randomly sorting practices 
within strata (using computer-generated random number 
sequences) and then allocating alternately. Clinics were 
not randomly assigned until they had agreed to participate. 
Individual patient-level randomisation was done by the 
general practice clinics directly using the BEST3 app, 
which used a computer-generated random number 
sequence. Potential participants in both the clinic-level and 
the patient-level randomisations were informed about the 
research and given the option to opt out of participation 
(including data collection) before knowing which group 
they would be assigned to.
All patients who were randomly assigned were 
followed passively for a weighted overall average of 
approximately 12 months (range 8–18 months). The 
chief investigator (RCF) and the lead statistician (PS) 
were masked to the aggregated results by group until 
follow-up was complete. Pathologists analysing endo-
scopic biopsies for Barrett’s oesophagus did not know 
whether the patient had undergone a Cytosponge-TFF3 
procedure.
Procedures
Participants randomly assigned to the usual care group 
received standard care, in which they received pre-
scriptions for acid-suppressant medication and their 
general practi tioner might have provided lifestyle advice 
or referral for an endoscopy, depending on the severity of 
their symptoms. Participants randomly assigned to the 
inter vention group received a letter inviting them to 
undergo a Cytosponge-TFF3 test and, if they expressed 
interest, were subse quently screened by a nurse via 
a telephone interview. Sometimes patients were not 
contactable by telephone or they changed their mind 
in the intervening period. The telephone screening 
interview included a symptom screen to ascertain whether 
participants were taking acid-suppressant therapy for 
heartburn-predominant symp toms and to exclude any 
participants who were not deemed to be suitable for 
the Cytosponge-TFF3 procedure. Partici pants were not 
offered a Cytosponge-TFF3 test if they had dysphagia (as 
the capsule might not reach the distal oesophagus) or if 
they were at an increased risk of bleeding because of 
known cirrhosis or varices, or if they were unable to stop 
taking antico agulants (see appendix p 26 for a full list of 
ineligibility criteria). Such participants were still included 
in the intention-to-treat analysis.
The Cytosponge consists of a polyester, medical-grade 
mesh sphere (3 cm in diameter), compressed within a 
gelatin capsule and attached to a thread (Cambridge 
University Hospitals NHS Foundation Trust [legal manu-
facturer]; produced by Europlaz, Essex, UK). The device 
was administered by a general practice clinic nurse or a 
Clinical Research Network nurse, following a training 
seminar and one-to-one training with an experienced 
practitioner (ID-B), until they were signed off as 
competent.
Samples collected from the Cytosponge procedure 
were processed centrally and assessed for the presence of 
Barrett’s oesophagus by use of haematoxylin and eosin 
staining and immunohistochemical staining for TFF3 
(Ventana Medical Systems, Tuscon, AZ, USA), as 
described previously.20 TFF3 staining was evaluated by 
experienced upper gastrointestinal pathologists, and 
consensus agreement from two or three pathologists was 
used in any cases of uncertainty. A sample in which no 
glandular cells were present was deemed to provide a low-
confidence result, as the device might not have reached 
the stomach and a diagnosis of distal Barrett’s oesophagus 
might have therefore been missed. Any sample with 
glandular groups of cells (indicating that the device had 
reached the stomach), and that did not have equivocal 
TFF3 staining, was considered a high-confidence result.
Patients with low-confidence or equivocal results, and any 
with processing failure, were offered a repeat Cytosponge-
TFF3 test. All patients with a positive TFF3 test result 
were offered an endoscopy to confirm the diagnosis of 
Barrett’s oesophagus and inform treatment. After com-
pletion of trial follow-up, a random sample of participants 
from each study group were invited to undergo a research 
endoscopy procedure. The results of these research 
endoscopies will be presented elsewhere. All endoscopy 
samples (both in the usual care group and in the 
intervention group) were analysed by the local pathologist. 
Participants with Barrett’s oesophagus diagnosed by use 
of the Cytosponge-TFF3 test also had their endoscopic 
biopsies centrally reviewed to confirm that intestinal 
metaplasia was present and to identify any dysplasia or 
cancer (by haematoxylin and eosin staining).
A census date 8–18 months after randomisation was set 
for each general practice clinic. Passive follow-up of 
all participants, irrespective of study group or whether 
they had undergone a Cytosponge-TFF3 procedure, was 
done up to the census date. Census dates were chosen 
independently of the randomisation, so as to have a 
weighted average follow-up of 12 months. The endpoint 
data collected were coded diagnoses of Barrett’s metaplasia, 
Barrett’s dysplasia, or oesophago-gastric adenocarcinoma, 
ascertained by at least one of the following three methods: 
(1) an electronic search of general practice clinic records 
for new diagnoses of Barrett’s oesophagus or oesophageal 
Articles
www.thelancet.com   Vol 396   August 1, 2020 337
adenocarcinoma, new referrals to gastro enterology depart-
ments, or new referrals for esoph agogastroduodenoscopy 
procedures within the study period, followed by a manual 
search of the clinical records for those patients with a 
potential diagnosis of Barrett’s oesophagus or oesophago-
gastric adenocarcinoma identified by the electronic search; 
(2) a full manual search of the general practice clinic 
records for all participants registered with that clinic; 
and (3) secure anonymous record linkage between 
participating general practice clinics and participating 
endoscopy units to identify individuals who were both 
study participants and who had been diagnosed with 
Barrett’s oesophagus or oesophago-gastric adenocarcinoma 
during the study period.
Outcomes
The primary outcome was the diagnosis of Barrett’s 
oesophagus at 12 months after enrolment, expressed as 
rate per 1000 person-years, in all participants in the 
intervention group (regardless of whether they had 
accepted the offer of the Cytosponge-TFF3 procedure) 
compared with all participants in the usual care group. 
The secondary outcomes were as follows: uptake of the 
Cytosponge-TFF3 procedure; the number of cases of 
Barrett’s oesophagus with dysplasia and intes tinal 
metaplasia-associated cancer, by stage at diag no sis; the 
positive predictive value of the Cytosponge-TFF3 test, 
measured in the subset of patients who had a sub sequent 
endoscopy after testing positive for TFF3; and the 
acceptability and safety of the Cytosponge-TFF3 test.
Statistical analysis
The results were statistically analysed by RM, MG, 
and PS. The statistical analysis plan for the study is 
provided in appendix (pp 90–125).
By use of a series of key assumptions about the 
prevalence of Barrett’s oesophagus, the proportion of 
endoscopy referrals, and the sensitivity and uptake of 
the Cytosponge-TFF3 procedure (appendix pp 103–107), 
the expected proportions of Barrett’s oesophagus diag-
noses over 12 months were calculated as 1·38% in the 
intervention group and 0·60% in the usual care group. 
On the basis of these assumptions, we calculated that 
a sample size of 6764 patients was required to achieve 
a power of 90% and a significance level of 5% if 
randomisation was done at the individual patient level.
To account for the cluster-randomisation design, a 
variance inflation factor was estimated by strata (defined 
by number of patients from each clinic who were ran-
domly assigned; 48–65, 66–90, 91–125, 126–175 or 
176–198 patients) for the cluster-randomised group, 
assuming that the intraclass correlation coefficient of the 
proportion of patients with Barrett’s oesophagus was 
0·025. The actual numbers of participants in each strata 
were divided by the variance inflation factor to yield the 
equivalent numbers of individually-randomised patients. 
Throughout the trial, we ensured that the projected sum 
of the equivalent size of the cluster-randomised group 
and the size of the individual patient-level randomised 
group was at least 6764 participants.
The primary endpoint of Barrett’s oesophagus diag-
noses (excluding cancer diagnoses) in both groups at 
12 months after enrolment, was analysed by use of a 
random-effects log-linear model. The number of Barrett’s 
oesophagus diagnoses was the Poisson-distributed out-
come, with a fixed effect for the strata, a random effect 
for each clinic, and an offset for the number of person-
years of follow-up. We assumed two different treatment 
effects (fixed rate ratios [RRs]) for the intervention group 
(one in the first 4 months and the second thereafter) that 
were eventually combined at a weight ratio of 1:2. In the 
usual care group, the treatment effect was assumed to 
be constant over time. The analysis was first done for 
the cluster-randomised group, then for the individual 
patient-randomised group (with no cluster effect), and 
finally for the whole dataset. When analysing the 
whole dataset, the individual patient-randomised group 
was assigned to a separate stratum. This method was 
approved by the MHRA.
As only aggregated data about age and sex were available, 
and we only had access to individual-level data on age, sex, 
and medication history for patients who successfully 
swallowed the Cytosponge, no adjustment was made for 
these factors in the analysis of the primary outcome. 
Statistical significance was based on a two-sided test with 
an α-value of 5%.
The uptake of the Cytosponge-TFF3 procedure was 
assessed as the number of patients who successfully 
swallowed the capsule, expressed as a proportion of the 
patients who were offered the procedure. The number of 
patients with Barrett’s oesophagus, Barrett’s oesophagus 
with dysplasia, or Barrett’s oesophagus and cancer is 
reported by study group and also by the number of 
participants who underwent the Cytosponge-TFF3 pro-
cedure in the intervention group. The positive predictive 
value of the Cytosponge-TFF3 procedure was calculated 
from the proportion of patients who underwent the 
procedure, in whom the subsequent endoscopy and 
pathological assessment confirmed the diagnosis of 
Barrett’s oesoph agus, Barrett’s dysplasia, or cancer (gold 
standard).
The acceptability of the Cytosponge-TFF3 procedure 
was estimated from a questionnaire, in which partici-
pants rated the procedure using an 11-point visual 
analogue scale (from 0 to 10); the median and IQR are 
reported, together with the proportion of participants 
who scored 5 or more (indicating that the test was 
somewhat acceptable).
The safety of the Cytosponge-TFF3 procedure was 
assessed by recording any adverse events and serious 
adverse events that had occurred within 7–14 days of 
undergoing the procedure. This assessment was done 
proactively by a nurse via a telephone call with patients. 
The proportion of patients who had an adverse event, 
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Figure 2: Trial profile
*202 (12%) of these 
1654 participants had a repeat 
Cytosponge test, as the first 
sample yielded a 
low-confidence result (defined 
as the absence of glandular 
cells in the sample) and a 
diagnosis of Barrett’s 
oesophagus could have 
therefore been missed; 
patients with equivocal 
results, or technical or 
processing failures, were also 
invited for a repeat test. 
TFF3=trefoil factor 3.
13 657 patients were identified as potential participants
143 opted out
13 514 randomly assigned
6531 assigned to the usual care group
143 excluded 
 7 were not eligible
 5 had a pre-existing diagnosis of
Barrett's oesophagus
 2 died before baseline
 136 withdrew consent 
6983 assigned to the intervention group
149 excluded
        27 were not eligible
8 had a pre-existing diagnosis of 
Barrett’s oesophagus
2 died before baseline  
17 could not be reached by study 
introductory letter
       122 withdrew consent
6834 were enrolled and offered the Cytosponge procedure 
 
4155 did not reply or declined offer
2679 responded and expressed an interest in undergoing the 
procedure
273 could not be contacted by telephone 
2406 were screened by telephone interview
310 failed the screening interview 
2096 were eligible to receive the Cytosponge-TFF3 procedure
346 did not book an appointment, or did 
book an appointment but did not attend
1750 underwent the Cytosponge procedure
1654 swallowed the Cytosponge successfully and produced a sample* 
6388 enrolled and included in the intention-to-treat analysis for 
diagnosis of Barrett’s oesophagus or cancer
96 were unable to swallow the Cytosponge
6834 enrolled and included in the intention-to-treat analysis for 
diagnosis of Barrett’s oesophagus or cancer
1423 did not test positive for TFF3
 1252 had a high-confidence negative result
 150 had a low-confidence negative result
 20 had an equivocal result
 1 processing failure
231 tested positive for TFF3
 221 accepted an invitation for an endoscopy
 10 did not accept an invitation for an endoscopy
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and the type and severity of adverse event, is reported. 
The adverse events were only collected for participants 
undergoing the Cytosponge-TFF3 procedure. Since 
endoscopy is standard of care, no adverse event data was 
collected in relation to this procedure.
Statistical analyses were done in Stata version 15 
(StataCorp LLC, College Station, TX, USA). Pseudo-
random numbers for all randomisations were generated 
in R (R Core Team [2019]).
An independent data monitoring committee and a trial 
steering committee, which included two lay members 
who provided a patient’s perspective, oversaw the trial.
The trial is registered with the ISRCTN registry, 
number ISRCTN68382401.
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author (RCF), RM, MG, 
BM, and PS had full access to all the data in the study and 
had final responsibility for the decision to submit for 
publication.
Results
Between March 20, 2017, and March 21, 2019, 113 general 
practice clinics located in socio-demographically diverse 
regions in England were enrolled, but four clinics 
dropped out shortly after being randomly assigned 
(three in the usual care group and one in the intervention 
group), leaving 109 clinics, comprising 13 657 patients. 
These patients were sent an introductory letter and 
given 14 days to opt out of the study. 143 of these patients 
opted out before individual patient-level randomisation, 
leaving 13 514 patients to be randomly assigned. After 
randomisation, 136 patients in the usual care group and 
122 patients in the intervention group withdrew. 
Additionally, 17 patients (ten in the intervention group 
and seven in the usual care group) were excluded 
because they had either died or had been diagnosed 
with Barrett’s oesophagus before randomisation, and 
17 patients (all in the intervention group) were excluded 
because their contact details were absent. Of the 
remaining 13 222 enrolled patients, 7839 patients from 
75 clinics were cluster-randomised (appendix p 127), 
and 5383 patients from 34 clinics were individually 
randomised (appendix p 128). Overall, 6388 participants 
were randomly assigned to the usual care group and 
6834 participants to the inter vention group (figure 2).
The demographics of the 13 222 participants included 
in the final analysis are summarised (table 1). The age 
distribution of participants who successfully swallowed 
the Cytosponge was similar to that of all participants. The 
randomly assigned clinics represented all ten deciles of 
the Index of Multiple Deprivation (data not shown). The 
median decile of deprivation among participants was 
seven (with one being the most deprived and ten the least 
deprived) and the lower quartile was four.
Following a written invitation, 2679 (39%) of 
6834 patients in the intervention group responded and 
expressed an interest in taking part in the Cytosponge-
TFF3 proce dure. Of these, 2096 (78%) participants 
were eligible following the telephone assessment, and 
1750 (65%) provided consent and underwent the pro-
cedure. 1654 (95%) of these participants (and 24% of all 
6834 participants in the intervention group) successfully 
swallowed the device, including 796 men (48%) and 
858 (52%) women, with a median age of 69 years 
(IQR 61–74; table 1). 311 (19%) of the 1654 participants 
who had successfully swallowed the device had a low-con-
fidence negative or equivocal test result, and depending 
on local capacity, were invited for a repeat Cytosponge-
TFF3 test. 202 (65%) of these participants attended the 
repeat appointment, 190 (94%) of whom successfully 
swallowed the device, leading to a further 140 patients 
producing a high-confidence (positive or negative) result. 
Overall, after the repeat test, 150 (9%) of the 1654 patients 
For more on R software see 
https://www.R-project.org/
All participants 
(n=13 222)
Usual care group 
(n=6388)
Intervention group
All participants 
(n=6834)
Participants who 
successfully 
swallowed the 
Cytosponge 
(n=1654)
Sex 
Male 6030 (46%)* ·· ·· 796 (48%)
Female 7155 (54%)* ·· ·· 858 (52%)
Age distribution, years
50–59 3171 (24%)* ·· ·· 326 (20%) 
60–69 4001 (30%)* ·· ·· 562 (34%)
70–79 4172 (32%)* ·· ·· 615 (37%)
80–89 1642 (12%) * ·· ·· 140 (8%) 
90–99 199 (2%) * ·· ·· 11 (1%) 
Size of general practice surgery
Small (48–90 patients) 2083 (16%) 1038 (16%) 1045 (15%) ··
Medium (91–160 patients) 6746 (51%) 3071 (48%) 3675 (54%) ··
Large (161–231 patients) 4393 (33%) 2279 (36%) 2114 (31%) ··
Medication use
Proton-pump inhibitor only 11 818 (92%)† ·· ·· 1434 (87%)‡
Histamine-2 receptor 
antagonists only
613 (5%)† ·· ·· 170 (10%)‡
Proton-pump inhibitor plus 
histamine-2 receptor 
antagonist
413 (3%) † ·· ·· 43 (3%)‡
Socioeconomic factors
Median Index of Multiple 
Deprivation decile§
7 (4–9) 6 (4–9) 7 (5–9) ··
Data are n (%) or median (IQR). Most data were aggregated by site; therefore, there are no data for some fields. 
*Baseline data were available in an aggregated form; data for age and sex are missing from one site. †Baseline data 
were available in an aggregated form; data for medication are missing from six sites. ‡Data for seven patients are not 
shown in the table, as they had records of over-the-counter acid-suppressant or other medications. §The Index of 
Multiple Deprivation (with a score of 1 indicating most deprived and a score of 10 indicating least deprived) scores 
were not available for individual participants and were calculated by assigning the score for each general practice clinic 
to each patient.
Table 1: Baseline characteristics of all randomly assigned participants
Articles
340 www.thelancet.com   Vol 396   August 1, 2020
who successfully swallowed the Cytosponge-TFF3 still 
produced a low-confidence negative result (figure 2).
Apart from the eight participants who were found, on 
review, to have pre-existing Barrett’s oesophagus, all 
participants who were invited for the Cytosponge-TFF3 
procedure were included in the final intention-to-treat 
analysis, regardless of whether or not they accepted 
the invitation. Barrett’s oesophagus diagnoses in both 
groups had to be identified from records of clinical 
coded diagnoses at all general practice clinics included 
in the study, the electronic records of local referral 
hospitals, or both, to ensure equity across the usual 
care and intervention groups (otherwise, diagnoses 
from the intervention group would have been more 
easily ascertained). One diagnosis of Barrett’s oesopha-
gus in a patient who had a positive Cytosponge-TFF3 
test result was omitted from the results, as a coded 
diagnosis was not identified by any of these data 
collection methods.
We identified 140 Barrett’s oesophagus diagnoses in 
the intervention group (127 in patients who underwent 
the Cytosponge-TFF3 procedure, and 13 in patients who 
did not undergo the Cytosponge-TFF3 procedure) 
compared with 13 diag noses in the usual care group 
(table 2, 3; see appendix pp 131–32 for the corresponding 
tables for randomisation groups and a breakdown of the 
length of Barrett’s oesophagus detected). 87 (69%) of the 
127 participants who were diagnosed with Barrett’s 
oesophagus from the Cytosponge-TFF3 procedure were 
male. As the results of the cluster-level randomisation 
and patient-level random isation both favoured the 
intervention group, an overall RR was calculated (table 2). 
The estimated cumulative rate of Barrett’s oesophagus at 
12 months was 20·2 per 1000 person-years in the 
intervention group and 2·0 per 1000 person-years in the 
usual care group (RR adjusted for cluster randomisation 
10·6 [95% CI 6·0–18·8], p<0·0001; table 2).
Of 1654 participants in the intervention group who 
successfully swallowed the Cytosponge device, 221 (13%)
with a positive TFF3 result had a subsequent confirmatory 
endoscopy. 127 (57%) of these participants were diagnosed 
with Barrett’s oesopha gus (one of whom had low-grade 
dysplasia, and three of whom had high-grade dysplasia), 
and four (2%) partici pants were diagnosed with stage I 
oesophago-gastric cancer. Therefore, the Cytosponge-
TFF3 procedure had a positive predictive value of 59% 
(131 of 221 confirmatory endoscopies in patients with a 
positive Cytosponge-TFF3 result) for Barrett’s oesophagus, 
dysplasia, or oesophago-gastric cancer (table 2, 3). Of 
those 90 participants who received a confirmatory 
endoscopy that did not result in a diagnosis of Barrett’s 
oesophagus, dysplasia, or cancer, a further 33 (37%) 
participants had intestinal metaplasia, identified from a 
single biopsy taken from the cardia or at the gastro-
oesophageal junction.
Using the available data, we calculated the empirical 
intraclass correlation coefficient of the proportion of 
patients with Barrett’s oesophagus, and found that this 
Usual care group 
(n=6388) 
Intervention 
group (n=6834)
Absolute difference 
in rates per 1000 
person-years 
(95% CI)
Overall rate ratio 
(95% CI); p value
Adjusted rate ratios (95% CI); p value
Cluster 
randomised group
Patient-level 
randomised group
Overall*
Number of participants diagnosed 
with Barrett’s oesophagus
13 (<1%) 140 (2%)† ·· ·· ·· ·· ··
Follow-up, person-years 6579 6952 ·· ·· ·· ·· ··
Rate of Barrett’s oesophagus, per 
1000 person-years
2·0 20·2‡ 18·3 (14·8–21·8) 10·2 (5·8–18·1) 10·0 (5·0–20·0); 
p<0·0001
12·0 (4·3–33·2); 
p<0·0001
10·6 (6·0–18·8); 
p<0·0001
Data are n (%), unless otherwise specified. *Overall adjusted rate ratio is a combined rate ratio of the two randomisation groups (cluster randomisation and individual patient-level randomisation) and accounts 
for clustering. †Number of participants diagnosed with Barrett’s oesophagus in the intervention group includes all participants who were offered the Cytosponge procedure. ‡The rate of Barrett’s oesophagus in 
the intervention group was calculated as the weighted average of the rate in the first 4 months of follow-up and the rate in the following months, with a weight ratio of 1:2. 
Table 2: Barrett’s oesophagus diagnoses in the usual care group compared with the intervention group
Usual care group 
(n=6388)
Intervention group
Underwent the 
Cytosponge 
procedure 
(n=1750)
Did not undergo 
the Cytosponge 
procedure 
(n=5084)
Overall 
(n=6834)
Grade of dysplastic Barrett’s oesophagus
No dysplasia 13 116 13 129 
Indefinite 0 7 0 7
Low-grade 0 1 0 1
High-grade 0 3 0 3
Total 13 127 13 140 
Oesophago-gastric cancer stage
I 0 4 1 5
II 1 0 0 0
III 1 0 0 0
IV 1 0 2 2
Total number of participants 
with Barrett’s oesophagus, 
cancer, or both
16 131 16 147 
Table 3: Number of individuals with Barrett’s oesophagus in the usual care group and intervention group 
with or without cancer, by grade of dysplasia and cancer stage
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value was similar to the expected empirical intraclass 
correlation coefficient (approximately 0·025).
For the secondary endpoints, we compared the number 
of endoscopic diagnoses of dysplasia and cancer in 
participants who were offered the Cytosponge-TFF3 
procedure with the number of these diagnoses in 
participants in the usual care group (intention-to-
treat analysis). Nine (<1%) of 6834 participants were 
diagnosed with dysplastic Barrett’s oesophagus (n=4) or 
stage I oesophago-gastric cancer (n=5) in the intervention 
group, whereas no participants were diagnosed with 
dysplastic Barrett’s oesophagus or stage I oesophago-
gastric cancer in the usual care group (table 3). Of these 
nine participants in the intervention group, eight were 
detected as a result of a positive Cytosponge-TFF3 test 
and a subsequent endoscopy and have all undergone a 
curative intervention (seven participants underwent 
endoscopic therapies, and one participant underwent an 
oesophagectomy for a stage IB cancer involving the first 
layer of the submucosa; appendix p 133). Among those 
who were offered the Cytosponge-TFF3 procedure but 
did not have the test (n=5084), one participant, who 
initially expressed interest in the procedure, but was 
referred for an endoscopy before it could be done, was 
diagnosed with early-stage cancer. Of all 6388 participants 
in the usual care group included in the final analysis, 
three participants were diagnosed with cancer, of whom 
two participants were palliative at presentation and 
died during the study period (appendix p 133). In the 
intervention group, two participants who did not 
undergo the Cytosponge-TFF3 test were diagnosed with 
stage IV oesophago-gastric cancer.
In the intervention group, an acceptability score for the 
Cytosponge-TFF3 procedure was provided by 1464 (89%) 
of 1654 participants approximately 1 week after they 
underwent the procedure. The median acceptability 
score was 9 (IQR 8–10), with 10 being completely 
acceptable, and 1427 (97%) of 1464 participants gave a 
score of 5 or higher (appendix p 134).
In the intervention group, one serious adverse event 
associated with the Cytosponge-TFF3 procedure was 
reported (detachment of the sponge from the thread 
requiring endoscopy to retrieve the expanded sponge 
with no adverse sequelae), and three serious adverse 
events unrelated to the procedure were reported (table 4). 
Of 1654 participants who successfully swallowed the 
Cytosponge device, 142 (9%) participants reported an 
adverse event, including 63 (4%) participants who had a 
sore throat that required medication or that interfered 
with eating (table 4).
Discussion
In this multicentre, pragmatic, randomised controlled 
trial we found that an invitation to have a Cytosponge-
TFF3 test led to increased diagnosis of Barrett’s 
oesophagus when compared with usual care by general 
practitioners. This comparison was made in patients 
identified as being high-risk for this condition, on the 
basis of a systematic search of electronic patient records 
for anti-gastro-oesophageal reflux medication. With 
regard to the secondary endpoint of the proportion of 
cancer diagnoses, although the numbers were small, we 
found that all participants in the intervention group who 
had dysplasia and cancer identified by the Cytosponge-
TFF3 procedure were suitable for curative therapy, 
whereas the cancers detected in the usual care group, and 
among participants who did not undergo a Cytosponge-
TFF3 procedure, had more advanced disease (four of six 
participants had stage III and IV cancer) and two of these 
were palliative at presentation and died during the study 
period.
For a device to be suitable for use in general practice 
clinics, its uptake, safety, and acceptability are key. The 
acceptability data obtained in our study are encouraging, 
with a median acceptability score of 9 out of 10, consistent 
with our previous trials.21,22 In this pragmatic trial done 
Adverse event severity (n=142) Total (n=142)
Low (n=112) Moderate (n=23) High (n=7)
Adverse event
Sore throat 57 (51%) 5 (22%) 1 (14%) 63 (44%)
Dyspepsia indigestion reflux 16 (14%) 3 (13%) 0 19 (13%)
Oesophageal or gastric pain 11 (10%) 2 (9%) 2 (29%) 15 (11%)
Feeling non-specifically unwell 6 (5%) 3 (13%) 0 9 (6%)
Nausea or vomiting 5 (4%) 3 (13%) 0 8 (6%)
Voice disturbance 3 (3%) 1 (4%) 0 4 (3%)
Diarrhoea or an upset stomach 4 (4%) 1 (4%) 0 5 (4%)
Chest pain or discomfort 2 (2%) 0 0 2 (1%)
Allergic reaction 1 (1%) 0 0 1 (1%)
Anxiety 1 (1%) 0 0 1 (1%)
Bad taste 1 (1%) 0 0 1 (1%)
Paroxysmal positional vertigo 1 (1%) 0 0 1 (1%)
Blood clot excretion 1 (1%) 0 0 1 (1%)
Vasovagal attack 1 (1%) 0 0 1 (1%)
Nosebleed 1 (1%) 0 0 1 (1%)
Headache 1 (1%) 1 (4%) 0 2 (1%)
Bloodshot eye 0 1 (4%) 0 1 (1%)
Chest infection 0 1 (4%) 0 1 (1%)
Abrasion 0 1 (4%) 0 1 (1%)
Fall 0 1 (4%) 0 1 (1%)
Serious adverse event
Unconscious after minor accident 0 0 1 (14%) 1 (1%)
Detachment of the sponge on 
day of the procedure
0 0 1 (14%) 1 (1%)
Hernia* 0 0 1 (14%) 1 (1%)
Myocardial infarction† 0 0 1 (14%) 1 (1%)
Data are n (%). All percentages calculated with the total number of participants in that column who had an adverse 
event as the denominator. The severity of adverse events was classified as low, moderate, or high by the nurse during 
the proactive follow-up telephone call with the patient. Serious adverse events were those classified according to the 
regulatory requirement for a device trial. *Hernia was repaired 5 days after the procedure. †Occurred 3 days after the 
procedure. 
Table 4: Adverse events in participants who underwent the Cytosponge-trefoil factor 3 (TFF3) procedure
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across a wide range of demographic areas across England, 
the proportion of all participants in the intervention group 
(n=6834) who expressed an interest in the Cytosponge-
TFF3 procedure was 39% (n=2679), and 24% (n=1654) of 
participants had the procedure and successfully swallowed 
the device, after accounting for inclusion and exclusion 
criteria and scheduling limitations. Since we anticipate 
the Cytosponge-TFF3 procedure being offered by a 
patient’s general practice clinician during a consultation 
for symptoms of gastro-oesophageal reflux or for a repeat 
prescription of acid-suppressant medication, as opposed 
to an unexpected written invitation, and since we will now 
be able to provide information regarding the efficacy of 
this procedure from this trial, we predict that the uptake of 
the Cytosponge-TFF3 procedure will increase substantially 
compared with that observed in this trial. This hypothesis 
will require further evaluation in future studies or in 
clinical implementation research.
The safety of the Cytosponge-TFF3 device has 
been evaluated previously in a systematic review25 of 
2672 procedures done across four different studies 
in the UK, the USA, and Australia. In this review,25 
2334 (97%) of 2418 patients swallowed the device 
successfully and there were two adverse events associated 
with the device; one was a detachment and one was a self-
limiting pharyngeal bleed. These results are similar to 
those of our trial. The proactive telephone call to patients 
7–14 days after they underwent the procedure also allowed 
us to collect data on side-effects. We found that 63 (4%) of 
1654 participants had a sore throat after the procedure, 
indicating that patients should be told that they might 
experience this adverse event after the procedure.
The prevalence of Barrett’s oesophagus or cancer in the 
221 participants who received an endoscopy after testing 
positive for TFF3 was 59% (n=131). We also identified 
intestinal metaplasia of the gastro-oesophageal junction 
and gastric cardia, which was extensive throughout the 
stomach in some cases, in 33 (15%) of 221 patients. These 
findings were not included in the primary endpoint, as 
intestinal metaplasia without visible columnar epithelium 
is not Barrett’s oesophagus. The guidelines for gastric 
intestinal metaplasia including the cardia were recently 
reviewed (2019), and UK and US societies suggest that, 
although the evidence is more scarce than it is for Barrett’s 
oesophagus, surveillance endo scopy should be considered 
when the gastric intestinal metaplasia is extensive or 
when there are other factors indicating an increased risk 
of gastric cancer, such as a family history.27,28
Overdiagnosis of cancer is a matter of much debate in 
the screening community, together with whether short 
segments (1 cm or less) of Barrett’s oesophagus should be 
considered as such. The TFF3 test is sensitive and detects 
some short segments of Barrett’s oesophagus. Additi-
onally, since this was a pragmatic trial that relied on a 
coded diagnosis of Barrett’s oesophagus, we also iden-
tified patients in the usual care group who had short 
segments of Barrett’s oesophagus (1 cm or less in length) 
and were diagnosed as having the condition, reflecting 
the variable practice in UK hospitals (appendix p 132). 
We expect that these patients can be reassured and 
probably do not require surveillance. This expectation is 
consistent with the clinical guidelines, which suggest that 
patients with over 1 cm of salmon-coloured epithelium 
containing intestinal metaplasia should be monitored.11,12 
With regard to the primary endpoint analysis, if we use 
a stringent criterion to diagnose the most clinically 
significant cases of Barrett’s oesophagus (ie those 3 cm 
or more in length; appendix p 132), four (<1%) of 
6388 participants would be diagnosed with Barrett’s 
oesophagus in the usual care group and 46 (1%) of 
6834 participants would be diagnosed with Barrett’s 
oesophagus in the intervention group. This result would 
still show a positive effect of introducing the Cytosponge-
TFF3 procedure into clinical care, with an RR of 10·5 
(95% CI 3·8–29·4), after accounting for clustering (data 
not shown).
Further guidance will be required to tailor the follow-up 
of patients diagnosed via the Cytosponge-TFF3 procedure, 
depending on their degree of risk of progressing to 
dysplasia or cancer according to the clinical surveillance 
guidelines. In the future, we expect that additional 
biomarkers will distinguish indolent Barrett’s oesophagus 
from Barrett’s oesophagus at high risk of progression, 
so that many patients can be followed up with the 
Cytosponge-TFF3 procedure, and endoscopy can be 
reserved for those at a high risk who are likely to 
require intervention. Identification of risk stratification 
biomarkers is an ongoing area of research.29
In this trial, patients were offered the Cytosponge-TFF3 
procedure if they required medication for heartburn 
symptoms. In many health-care systems, a one-off endo-
scopy would be considered for these patients given that 
many require long-term medication (ie, for 3 years or 
more). The sensitivity and specificity of the Cytosponge-
TFF3 procedure have been evaluated previously,22 and our 
trial was not designed to re-evaluate these aspects. 
However, based on the number who had an endoscopy 
following a Cytosponge-TFF3 procedure but did not 
have Barrett’s oesophagus or cancer (n=90), and on the 
number who successfully swallowed the Cytosponge-
TFF3 but did not have Barrett’s oesophagus or cancer 
(n=1523), we estimated the specificity of the Cytosponge-
TFF3 procedure to detect Barrett’s oesophagus, dysplasia 
or cancer to be 94%. In the future, consideration should 
be given to the ideal enrichment criteria, which might 
include a different age cutoff for men compared with 
women because of the difference in incidence (ie, 
87 [69%] of 127 Barrett’s oesophagus diagnoses in patients 
who successfully swallowed the Cytosponge were male), 
and also the inclusion of other risk factors, such as body-
mass index.
Among the strengths of our trial is the real-world 
implementation of the Cytosponge-TFF3 procedure, 
including the administration of the device by a nurse in 
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the community setting. The TFF3 test was done in a 
clinically certified laboratory, and the results were 
communicated in real time. The use of coding to ascer-
tain diagnoses of Barrett’s oesophagus, dysplasia, and 
cancer ensured equity across both study groups. Since 
informed consent from individual patients was obtained 
only for those who underwent the Cytosponge-TFF3 
procedure, the use of coding was the only way to ascertain 
the diagnoses for participants in the usual care group 
and those in the intervention group who declined the 
invitation to undergo the Cytosponge-TFF3 procedure.
This trial has some limitations. First, those participants 
who agreed to undergo the Cytosponge-TFF3 procedure 
might have had more problematic symptoms than those 
who did not accept the offer of the procedure. We 
eliminated this bias by analysing the data of the whole 
trial as an intention-to-treat analysis. Second, 150 (9%) of 
1654 participants still had a low-confidence result after 
the offer of a repeat test. Work is ongoing to find out how 
to reduce this outcome. Third, there were slightly more 
women than men agreeing to undergo the Cytosponge-
TFF3 procedure, even though Barrett’s oesophagus is 
more prevalent in men than in women. In future, 
strategies to encourage men to attend the procedure, and 
whether to alter the threshold for testing men versus 
women, should be considered. Finally, variation in 
the quality of endoscopies was apparent across the 
24 hospitals that took part in the study.30 We (MDP) did a 
central review of video images and liaised with hospitals 
to ensure consistency in reporting. Currently, the TFF3 
test requires manual reading by a pathologist trained in 
analysing these specimens, which are much larger and 
more cytological in nature than endoscopic biopsies. 
Work is underway to use deep machine learning to 
automate the quality control and assist the pathologists 
in their diagnosis, thus substantially reducing the 
reporting time and observer bias.
In conclusion, for patients with heartburn-predominant 
symptoms requiring acid-suppressant therapy for at least 
6 months, the Cytosponge-TFF3 procedure is a feasible, 
safe, and generally acceptable test to administer in the 
general practice clinic setting. This procedure results in 
improved detection of Barrett’s oesophagus, thus 
enabling a more proactive approach for the identification 
and minimally invasive treatment of dysplasia and early 
cancer. An economic evaluation will establish the effect of 
this strategy, taking into account the additional number 
of endoscopies required as a result of the Cytosponge-
TFF3 procedure.
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